

# Genetic Determinants of Antibiotic Resistance in Hospital and Community Isolates of *Klebsiella pneumoniae* and *Escherichia coli*

Farzaneh Dehghan,<sup>1</sup> Nader Zolghadri,<sup>2</sup> and Afsaneh Karmostaji<sup>3,\*</sup>

<sup>1</sup>Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

<sup>2</sup>Department of Mathematics, Islamic Azad University, Sama Colledge, Bandar Abbas, Iran

<sup>3</sup>Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

\*Corresponding author: Afsaneh Karmostaji, Infectious and Tropical Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Tel: +98-763666365, Fax: +98-7636670724, E-mail: afsanehkk@yahoo.com

Received 2017 January 14; Revised 2017 April 09; Accepted 2017 April 15.

## Abstract

**Background:** Multi-drug resistant *Escherichia coli* and *Klebsiella pneumoniae* with various resistance determinants are a major concern in hospital and community acquired infections around the world.

**Objectives:** To describe the presence of  $bla_{CTX-M}$ ,  $bla_{TEM}$ ,  $bla_{PER}$ ,  $bla_{VEB}$ , and integrons class 1, 2, 3 and extended spectrum  $\beta$  lactamase (ESBL) phenotype in *E. coli* and *K. pneumoniae* isolates from clinical samples of inpatients and outpatients.

**Methods:** One hundred and eighty six *E. coli* and fifty-eight *K. pneumoniae* were collected. Antimicrobial susceptibility test was performed by disk diffusion method. Extended-spectrum beta-lactamase phenotype were screened by phenotypic confirmatory test. PCR assay was performed for  $bla_{TEM}$ ,  $bla_{CTX-M}$ ,  $bla_{PER}$  and  $bla_{VEB}$  and class 1, 2, 3 integrase genes. Statistical analysis was performed by chi-squared test.

**Results:** Extended-spectrum beta-lactamase phenotype was detected in 49 (26.3%) *E. coli* and 19 (32.8%) *K. pneumoniae* isolates.  $bla_{VEB}$  gene in 32 (17.2%) *E. coli* and 5 (8.6%) *K. pneumoniae* isolates.  $bla_{PER}$  gene in 4 (2.1%) *E. coli* and 0 (0%) *K. pneumoniae* isolates.  $bla_{CTX-M}$  gene in 113 (60.7%) *E. coli* and 34 (58.6%) *K. pneumoniae* isolates.  $bla_{TEM}$  gene in 106 (57%) *E. coli* and 25 (43.1%) *K. pneumoniae* isolates. One hundred and nine (58.6%) of *E. coli* and 33 (56.9%) of *K. pneumoniae* were carrying Class 1 integron and 18 (9.7%) of *E. coli* and 3 (5.2%) of *K. pneumoniae* were carrying Class 2 integron. Class 3 integron was not detected.

**Conclusions:** High prevalence of ESBLs in *E. coli* and *K. pneumoniae* isolated from the community and hospital acquired infections could lead to the wide spread of multi-drug resistance clones that also contain new mechanism of resistance.

**Keywords:** Community-Acquired Infection,  $\beta$  Lactamases, Hospital Infections, *Klebsiella pneumoniae*, *Escherichia coli*, Integrons

## 1. Background

*Klebsiella pneumoniae* and *Escherichia coli* are Gram negative opportunistic pathogens from the family of *Enterobacteriaceae*. National Health Care safety Network in their report of between 2009 - 2010, described *E. coli* as 8% and *K. pneumoniae* as 11.5% of health care associated infections (1). From the early 1970s, *K. pneumoniae* was reported as one of the major causes of Hospital acquired infections, worldwide. Also *K. pneumoniae* is considered as a major cause of community-acquired infections including severe pneumonia in alcoholic and diabetic patients, urinary tract infections and liver abscess (2).

Resistance to extended-spectrum cephalosporins is a well-known problem among *Enterobacteriaceae* (3). Extended-spectrum beta-lactamase (ESBL) with the capability of hydrolysing oxyimino-cephalosporins, and monobactams, except cephamycins or carbapenems, first described in 1983 (4). The majority of Ambler class A beta-lactamases are TEM beta-lactamase responsible for resistance to ampicillin, penicillin and first-generation

cephalosporins such as cephalothin. Occurrence of mutations in the  $bla_{TEM-1}$  gene, could lead to ESBL phenotype and increase the hydrolysis capabilities of particular extended-spectrum cephalosporins and aztreonam (5). Another class A beta-lactamases, Cefotaximases (CTX-M) have the capability of hydrolysing cefotaxime and aztreonam and worldwide distribution in community and hospitals is mediated by integrons and insertion sequences (6). The VEB-1 beta lactamase is responsible for a higher level of resistance to ceftazidime than to cefotaxime (7). PER-1 with the capability of hydrolyzing penicillins, oxyimino-cephalosporins and aztreonam, with high prevalence in non-fermentative Gram negative bacilli, such as *Pseudomonas aeruginosa*, *Acinetobacter* spp., and *Alcaligenes faecalis*, has also recently been detected in *Enterobacteriaceae* (8). Carbapenem resistance in *Enterobacteriaceae* is mediated by genes located on integrons, such as  $bla_{KPC}$ , the gene encoding an Ambler molecular class A enzyme, or  $bla_{NDM}$  the gene encoding New Delhi metallo-beta-lactamase, which give them the potential of transmission in the community and hospital setting (3).

Four types of antibiotic integrons have been classified based on the *intI* sequence (9). Integrons are mobile genetic elements that consist of two conserved segments; the 5' conserved segment contains the *intI* gene, the *attI* site, and the common promoter *Pant* and; the 3' conserved segment which includes an antiseptic resistance gene (*qacED1*), a sulphonamide resistance gene (*sulI*) and an ORF (*orf5*) of unknown function. Class 2 integrons are similar to class 1 integrons (10). Most integrons from clinical isolates belong to class 1. The prevalence of the class 1 integron in clinical isolates of *E. coli* is reported between 33% to 49% and in commensal isolates between 11% - 42% (11).

## 2. Objectives

Since the existence of integrons in commensal opportunistic strains could serve as a reservoir for the spread of resistance genes in the community and hospital, the present study was conducted to describe the presence of four genetic variants of extended spectrum  $\beta$  lactamase including *bla*<sub>CTX-M</sub>, *bla*<sub>TEM</sub>, *bla*<sub>PER</sub>, *bla*<sub>VEB</sub> associated with Classes 1, 2, 3 integrons in *E. coli* and *K. pneumoniae* isolates from community-acquired and hospital acquired infections.

## 3. Methods

### 3.1. Subjects

Four groups of patient were included in the present study in May 2014 and February 2015. The four groups of patients included in the study, were as follows: Groups 1 and 2: Ninety-nine inpatients and Eighty-seven outpatients, infected with *E. coli* making a total of One hundred eighty six. Groups 3 and 4: Thirty-four inpatients and twenty-four outpatients (totaling 58); infected with *K. pneumoniae*.

### 3.2. Ethics and Consent

The study was approved by the Hormozgan University of Medical Sciences ethics committee according license number Hums.rec.1394.148.

### 3.3. Bacterial Isolates

*Escherichia coli* and *K. pneumoniae* were identified by biochemical tests (12). Bacterial isolates were collected from clinical specimens of affected patients, (e.g., urine, wound, sputum, ascites fluid, cerebrospinal fluid, peritoneum).

### 3.4. Antimicrobial Susceptibility Testing

Antimicrobial susceptibilities were determined by disk diffusion method in accordance with the clinical and laboratory standards institute (CLSI) guidelines. The following antibiotic disks (MAST Ltd, UK) were used: imipenem (10  $\mu$ g), gentamicin (10  $\mu$ g), ofloxacin (5  $\mu$ g), ceftriaxone (30  $\mu$ g), cefotaxime (30  $\mu$ g), cefepime (30  $\mu$ g), aztreonam (30  $\mu$ g), ceftazidime (30  $\mu$ g), amikacin (30  $\mu$ g), trimetoprim/ sulfametoxazol (1.25/23.75  $\mu$ g), ciprofloxacin (5  $\mu$ g), cefixime (5  $\mu$ g). ESBL producing isolates were screened by phenotypic confirmatory test (PCT) using ceftazidime and clavulanic acid (13).

### 3.5. PCR for Identification of Antibiotic Resistance Determinants

DNA was extracted by boiling. The extracted DNA was used as a template for amplification of *bla*<sub>TEM</sub>, *bla*<sub>CTX-M</sub>, *bla*<sub>PER</sub>, *bla*<sub>VEB</sub> using 4 primer pairs (Gen Fanavaran Ltd). Table 1 shows the primer sequence, annealing temperature and product size of target genes (14-16). Multiplex PCR was performed for the identification of Class 1, 2, 3 integrons as described by Dillon et al., (17). The PCR amplification was performed in a total volume of 25  $\mu$ L containing 3  $\mu$ L of DNA template, 10 pmol of each primer and 1.5 U of Taq DNA polymerase, in 10 $\times$  PCR buffer containing 1.5 mM MgCl<sub>2</sub> and 200  $\mu$ M of each deoxynucleoside triphosphate (Cinagen Ltd, Iran). The annealing temperatures are presented in Table 1. Expected amplified products, were separated by electrophoresis on 1% agarose gel containing 0.5  $\mu$ g/mL ethidium bromide and photographed under UV illumination.

### 3.6. Statistical Analyses

Statistical analyses were performed using the SPSS 21 and Excel (Microsoft Corp) software programs, employing the chi-square test, and P values less than 0.05 were considered statistically significant.

## 4. Results

### 4.1. Strain Identification

A total of 186 *E. coli* isolates, 125 isolates (67.2%) were from female and 61 (32.8%) were from males. This comprised of 167 isolates (89.8%) from urine, 7 from wound (3.8%), 6 from throat (3.2%), 3 from Ascites fluid (1.6%) and 1 from other samples such as cerebrospinal fluid, Peritoneum and sputum (0.5%). ninety-nine out of 186 *E. coli* isolates (53.2%) were obtained from inpatients. Samples from inpatients were obtained from any of the wards including, internal medicine 30 (30.3%), pediatrics 24 (24.2%), intensive care units 12 (12.1%), Gynecology 9 (9.1%) and 24 (24.2%) were from other different wards. Eighty-six isolates

**Table 1.** Primer Pairs Used for Amplification in This Study

Primer Name	Sequence (5'-3')	Product Size, bp	Target	Annealing, °C	Reference
<b>Veb-1-f</b>	CGA CTT CCA TTT CCC GAT GC	643	<i>Bla<sub>VEB</sub></i>	62	(14)
<b>Veb-1-r</b>	GGA CTC TGC AAC AAA TAC GC				
<b>Per-1-f</b>	ATG AAT GTC ATT ATA AAA GC	927	<i>Bla<sub>PER</sub></i>	50	(14, 16)
<b>Per-1-r</b>	TTAATTGGGCTTAGGG				
<b>TEM-F</b>	GAGTATTCAACATTTCGGTGTC	851	<i>Bla<sub>TEM</sub></i>	63	(14)
<b>TEM-R</b>	TAATCAGTGAGGCACCTATCTC				
<b>CTX-m1 F</b>	GACGATGCTACTGGCTGAGC	499	<i>Bla<sub>CTX-M</sub></i>	55	(15)
<b>CTX-m1 R</b>	AGCCGCCGACGCTAATACA				
<b>Int-1F</b>	CAGTGGACATAAGCCTGTTC	160	Int 1	62	(17)
<b>Int-1R</b>	CCCAGGCATAGACTGTA				
<b>Int-2F</b>	GTAGCAAACGAGTGACGAAATG	788	Int 2	62	(17)
<b>Int-2R</b>	CACGGATATGCGACAAAAGGT				
<b>Int-3F</b>	GCCTCCGGCAGCGACTTTCAG	979	Int 3	62	(17)
<b>Int-3R</b>	ACGGATCTGCCAACCTGACT				

out of 87 (98.8%) outpatient *E. coli* isolates, obtained from urine samples.

A total of 58 *K. pneumoniae* isolates, 22 isolates (37.9%) were from female and 18 (31%) were from males. This comprised of 34 (58.6%) isolates from inpatients, which were obtained from intensive care unit 12 (20.7%), pediatrics7 (12.1%), emergency 7 (12.1%), internal medicine 4 (6.9%), burn 1 (1.7%), surgery 1 (1.7%), ear, nose, and throat department 1 (1.7%) and neurology department 1 (1.7%).

#### 4.2. Antimicrobial Susceptibility Testing

Forty-nine (26.3%) *E. coli* and 19 (32.8%) *K. pneumoniae* isolates presented with ESBL phenotype. ESBL ratio between inpatient and outpatient in *E. coli* isolates was 31/18 (31.3/20.7%) and in *K. pneumoniae* isolates was 13/6 (38.2%/25%). Antibiotic susceptibility of *E. coli* and *K. pneumoniae* isolates are shown in Table 2. Imipenem, ceftazidime and cefepime were the most effective betalactams against *E. coli* (92.5% susceptible) and *K. pneumoniae* (65.5% susceptible). The most resistance rate in isolates was on tetracycline with 65.6% resistance in *E. coli* and 72.4% resistance in *K. pneumoniae*.

Resistance rate of ESBLs producing *K. pneumoniae* to advanced generation cephalosporins are as follows: nineteen (100%) resistant to ceftazidime, 17 (89.5%) resistant to ceftriaxone and cefotaxime, 11 (57.9%) resistant to cefixime and 6 (31.6%) resistant to fourth generation cephalosporin and cefepime. Resistance rate of ESBLs *E. coli* to cefotaxime, cef-

triaxone and cefixime, ceftazidime and cefepime consequently were 47 (95.9%), 46 (93.9%), 32 (65.3%), 30 (61.2%).

#### 4.3. Detection of Beta-Lactamase Genes

The prevalence of  $\beta$  lactamase genes and integrons are shown in Tables 3 and 4. Class 1 integron in *E. coli* (58.6%) was higher than in *K. pneumoniae* (56.9%) and the same was for Class 2 at 9.7 vs 5.2%. Sixty-two isolates (33.3%) of *E. coli* and 23 isolates (39.6%) of *K. pneumoniae* were carriers of both *bla<sub>TEM</sub>* and *bla<sub>CTX-M</sub>* genes. Five *E. coli* isolates and one *K. pneumoniae*, were carriers of both integron Class 1 and 2. One of the *E. coli* and 2 isolates of *K. pneumoniae*, were carriers of more than one of the beta-lactamase genes tested in our study. Characteristics of these isolates are shown in Table 5.

#### 4.4. Statistical Analyses

We found significant differences in ESBLs phenotype in *E. coli* isolated from inpatient compared to community acquired isolates ( $P = 0.050$ ). Although these differences were not significant in *K. pneumoniae* ( $P = 0.145$ ). A significant association of ESBL presentation in *E. coli* was observed with resistance to ceftazidime, cefepime, ceftriaxone, aztreonam, cefexime, cefotaxime and ofloxacin ( $P = 0.000$ ) and gentamicin ( $P = 0.001$ ). In *K. pneumoniae* isolates, significant association was found with resistance to ceftazidime ( $P = 0.000$ ) and cefepime ( $P = 0.001$ ), and ceftriaxone ( $P = 0.000$ ), aztreonam ( $P = 0.009$ ), cefexime (0.002), cotrimoxazole (SXT) ( $P = 0.000$ ) and cefotaxime

**Table 2.** Frequency (%) of Sensitivity Rate in *E. Coli* and *K. Pneumoniae* Isolates from Inpatient and Outpatient<sup>a</sup>

Antibiotics	<i>E. Coli</i>			<i>K. Pneumoniae</i>		
	Inpatient, N = 99	Outpatient, N = 87	Total, N = 186	Inpatient, N = 34	Outpatient, N = 24	Total, N = 58
CAZ	57 (57.6)	64 (73.6)	121 (65.1)	13 (38.2)	17 (70.8)	30 (51.7)
CPM	59 (59.6)	63 (72.4)	122 (65.6)	16 (47.1)	18 (75)	34 (58.6)
CRO	33 (33.3)	54 (62.1)	87 (46.8)	11 (32.3)	18 (75)	29 (50)
AZI	40 (40.4)	57 (65.5)	97 (52.2)	13 (38.2)	18 (75)	31 (53.4)
IPM	92 (92.9)	80 (91.9)	172 (92.5)	21 (61.8)	17 (70.8)	38 (65.5)
AN	96 (97)	81 (93.1)	177 (95.2)	29 (85.3)	21 (87.5)	50 (86.2)
CP	59 (54.5)	55 (63.2)	109 (58.6)	25 (73.5)	22 (91.7)	47 (81.1)
SXT	31 (31.3)	46 (52.9)	77 (41.4)	18 (52.9)	16 (66.7)	34 (58.6)
TE	28 (28.3)	33 (37.9)	61 (32.8)	8 (23.5)	3 (12.5)	11 (19)
OFX	53 (53.5)	54 (62.1)	107 (57.5)	15 (44.1)	18 (75)	33 (56.9)
GM	63 (63.6)	68 (78.2)	131 (70.4)	23 (67.6)	20 (83.3)	43 (74.1)
CTX	28 (28.3)	50 (57.5)	78 (41.9)	10 (29.4)	15 (62.5)	25 (43.1)
CFM	34 (34.3)	56 (64.4)	90 (48.4)	12 (35.3)	17 (70.8)	29 (50)

Abbreviations: AN, Amikacin; AZI, Aztreonam; CAZ, Cefazidime; CFM, Cefexime; CP, Ciprofloxacin; CPM, Cefepime; CRO, Ceftriaxone; CTX, Cefotaxime; GM, Gentamicin; IPM, Imipenem; OFX, Ofloxacin; SXT, Cotrimoxazole; TE, Tetracycline.

<sup>a</sup>Values are expressed as No. (%).

**Table 3.** Molecular Characteristics of *E. Coli* Isolates with ESBL Phenotype<sup>a</sup>

Bacteria	No.	ESBLs Genes				Integrans	
		<i>bla</i> <sub>TEM</sub>	<i>bla</i> <sub>CTX-M</sub>	<i>bla</i> <sub>PER</sub>	<i>bla</i> <sub>VEB</sub>	Class 1	Class 2
<i>E. coli</i>							
Inpatient	99 (53.2)	57 (57.6)	71 (71.7)	3 (3)	19 (19.2)	66 (66.7)	11 (11.1)
Outpatient	87 (46.8)	49 (56.3)	42 (48.3)	1 (1.1)	13 (14.9)	43 (49.4)	7 (8.04)
<b>Total</b>	<b>186 (100)</b>	<b>106 (57)</b>	<b>113 (60.8)</b>	<b>4 (2.2)</b>	<b>32 (17.2)</b>	<b>109 (58.6)</b>	<b>18 (9.7)</b>

<sup>a</sup>Values are expressed as No. (%).

**Table 4.** Molecular Characteristics of *K. Pneumoniae* Isolates with ESBL Phenotype<sup>a</sup>

Bacteria	No.	ESBLs Genes				Integrans	
		<i>bla</i> <sub>TEM</sub>	<i>bla</i> <sub>CTX-M</sub>	<i>bla</i> <sub>PER</sub>	<i>bla</i> <sub>VEB</sub>	Class 1	Class 2
<i>K. pneumoniae</i>							
Inpatient	34 (58.6)	18 (52.9)	22 (64.7)	0	1 (2.9)	21 (61.8)	2 (5.9)
Outpatient	24 (41.4)	7 (29.2)	12 (50)	0	4 (16.7)	12 (50)	1 (4.2)
<b>Total</b>	<b>58 (100)</b>	<b>25 (43.1)</b>	<b>34 (58.6)</b>	<b>0</b>	<b>5 (8.6)</b>	<b>33 (56.9)</b>	<b>3 (5.2)</b>

<sup>a</sup>Values are expressed as No. (%).

( $P = 0.001$ ). There was not significant association between class 1 and class 2 integrans and ESBL presentation in *E. coli* ( $P = 0.44$ ). A significant association of ESBL presentation in *K. pneumoniae* was observed with class 1 integron ( $P = 0.0018$ ), but class 2 integron ( $P = 0.47$ ).

**Table 5.** Characteristics of *E. Coli* and *K. Pneumoniae* Isolates That Contains Integrons and More Than One of the  $\beta$  Lactamase Genes

Isolate	Bacteriae	Inpatient/Outpatient	Sex	Site of Isolation	Bla Genes and Integrones	Pattern of Resistance
174E	<i>E. coli</i>	Inpatient	male	CSF	Bla <sub>CTX-M</sub> , Bla <sub>PER</sub> , Bla <sub>VEB</sub> , Bla <sub>TEM</sub> , Class 2	CRO,CTX,CPM,AZI,CAZ,SXT,CP,CFM,
74K	<i>K. pneumoniae</i>	Outpatient	male	urine	Bla <sub>CTX-M</sub> , Bla <sub>VEB</sub> , Bla <sub>TEM</sub> , Class 1	GM,AN,CFM,CP,IPM,AZI,TE,CTX,CPM
43K	<i>K. pneumoniae</i>	Inpatient	female	urine	Bla <sub>CTX-M</sub> , Bla <sub>VEB</sub> , Bla <sub>TEM</sub> , Class 1	SXT,GM,CRO,OFX,CAZ,TE,CTX

## 5. Discussion

Multi-drug resistant isolates of *E. coli* and *K. pneumoniae* are increasingly reported in hospital and community settings around the world. We analyzed the level of antimicrobial resistance, the ESBL presentation and the presence of molecular determinants of resistance including integrons and beta-lactamases-encoding genes in the most prevalent species of *Enterobacteriaceae* isolated from different samples of inpatient and outpatient. The emergence of community acquired ESBL producing *E. coli* was first reported in 1988 and since then we have been faced with increasing reports from around the world (4), 7.1% in Brazil (18), 7% in Hong Kong (19) to 28.1% in France (20) and 67.3 in India (21) to higher level of 32% in Iran (22) which was more than the present study (20.7%).

In Iranian study, the frequency of ESBL phenotype in *K. pneumoniae* in community acquired infections respectively were 52% (23) which was more than our results (25%). We didn't find significant differences in ESBLs phenotype in *K. pneumoniae* isolated from inpatient compared to community acquired isolates. However, the frequency of ESBL phenotype in *K. pneumoniae* in inpatient in the present study (38.2%), was similar to Kashan study (35%), (23). And less than Tehran study (64%) (24). Significant differences in ESBLs phenotype in *E. coli* isolated from inpatient compared to outpatient, in our study, may be due to the selective pressure of excessive consumption of antibiotics in hospital.

In the present study, the ESBLs producing isolates showed resistance to most antibiotics including advanced generation cephalosporins (31.6% to 100%), which was consistent with other studies in Italy that reported resistance rate of between 41.9 % to 87.0 % for *K. pneumoniae* to third generation cephalosporins from 2010 to 2012 (25). In Iran, the rate of resistance to third generation cephalosporins amongst ESBL producing *K. pneumoniae* was between (55%, ceftriaxone), to (67.4%, cefexime) (26). Although these enzymes are not effective on carbapenems, since the cephalosporin resistance results in the use of carbapenem in the treatment of infections, these isolates

might be exposed to carbapenem and became resistance (27).

Furthermore, the presence of class 1 and class 2 integrons in these isolates might be mediated resistance to other non beta-lactam antibiotics such as cotrimoxazole, tetracycline, gentamicin and plasmid that carry ESBL genes and can transport resistance genes of other classes of antibiotics (28). Thus, ESBL-producing isolates may exhibit resistance to multiple class of antibiotics.

The most prevalent beta-lactamase genes in the studied isolates was *bla*<sub>CTX-M</sub> which is supported by previous studies in Iran and other countries. ESBL producing *Klebsiella* in Iranian studies were 35% in Kashan of which 80% carried the *bla*<sub>CTX-M</sub> genes (24). According to a French study, the prevalence of CTX-M-producing *E. coli* among the total number of *E. coli* isolates was 60.8%, and the occurrence of CTX-M-producing *E. coli* among ESBL-producing *E. coli* isolates was 39.8% (20). A polish study revealed that Most of the ESBL-producing isolates (75.7%) had a *bla*<sub>CTX-M</sub> gene (29). Some studies have indicated that CTX-M-producing *E. coli* and *K. pneumoniae* have been imported from community acquired urinary tract infections into the hospital setting (27).

In spite of what was expected, in the present study, prevalence of *bla*<sub>VEB</sub> in outpatients was more than in inpatients (16.7% vs. 2.9%). The small number of samples harbored this gene, can result in this finding. Amongst 34 ESBL producing *E. coli* isolates from community acquired urinary tract infections in Cambodia, all were positive for *bla*<sub>CTX-M</sub> and negative for *bla*<sub>VEB</sub> and *bla*<sub>TEM</sub> in 26 (76.4%) of the ESBL-carrying strains was reported (29). One hundred and thirty seven *E. coli* (73.6%) were not ESBL producing according to PCT. 121 (88.3%) isolates harbored at least one of the studied genes and in *K. pneumoniae* 39 isolates were not ESBL producing whereas 24 (61.5%) harbored ESBL genes. Presence of beta-lactamase genes in isolates lacking ESBL phenotype, indicates the presence of resistance gene pools in studied isolates causing a risk of resistance gene expression and ESBL phenotype in case of uncontrolled consumption of antibiotics.

Only one *E. coli* showed ESBL phenotype, without hav-

ing any of the studied beta-lactamase genes and integrons indicates that the presence of this phenotype in isolates could mainly be due to the presence of these genes. Compared with other studies in Iran (52% class I integron and 2.5% class 2 integron) (9) and Kenya (35% class I integron) (30), the prevalence of integrons in all isolates and even in inpatient isolates was higher. Integrons have the main role in the acquisition and dissemination of resistance genes amongst bacteria. We also found a significant association of ESBL presentation in *K. pneumoniae* with class 1 integron. This might predict the dissemination and presence of various resistance determinants in nosocomial and community acquired isolates.

One limitation of the current study is the lack of assessment of cassette arrangement in integrons that could provide useful information about resistance gene pools of these isolates. The present study provides evidence indicating the exposure of dissemination of clones with multiple resistance determinants in community and hospital setting in our region. These clones may also acquire other new resistance genes via integrons. Further investigation on surveillance of resistance and molecular typing is recommended to distinguish genetic relatedness and route of transmission of isolates.

## Acknowledgments

This study was extracted from a research project conducted at the Hormozgan University of Medical Sciences. We thank the vice chancellor for research at Hormozgan University of Medical Sciences, molecular medicine research center and infectious and tropical diseases research center.

## Footnotes

**Financial Disclosure:** This work was supported by grants from Hormozgan University of medical sciences.

**Conflict of Interests:** All authors have no conflicts of interest to declare.

## References

- Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol.* 2013;**34**(1):1-14. doi: [10.1086/668770](https://doi.org/10.1086/668770). [PubMed: [2322186](https://pubmed.ncbi.nlm.nih.gov/2322186/)].
- Vuotto C, Longo F, Balice MP, Donelli G, Varaldo PE. Antibiotic Resistance Related to Biofilm Formation in *Klebsiella pneumoniae*. *Pathogens.* 2014;**3**(3):743-58. doi: [10.3390/pathogens3030743](https://doi.org/10.3390/pathogens3030743). [PubMed: [25438022](https://pubmed.ncbi.nlm.nih.gov/25438022/)].
- Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. *Clin Infect Dis.* 2011;**53**(1):60-7. doi: [10.1093/cid/cir202](https://doi.org/10.1093/cid/cir202). [PubMed: [21653305](https://pubmed.ncbi.nlm.nih.gov/21653305/)].
- Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. *J Antimicrob Chemother.* 2005;**56**(1):52-9. doi: [10.1093/jac/dki166](https://doi.org/10.1093/jac/dki166). [PubMed: [15917288](https://pubmed.ncbi.nlm.nih.gov/15917288/)].
- Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. *Drugs.* 2003;**63**(4):353-65. doi: [10.2165/00003495-200363040-00002](https://doi.org/10.2165/00003495-200363040-00002). [PubMed: [12558458](https://pubmed.ncbi.nlm.nih.gov/12558458/)].
- Mendonca N, Leitao J, Manageiro V, Ferreira E, Canica M. Spread of extended-spectrum beta-lactamase CTX-M-producing *Escherichia coli* clinical isolates in community and nosocomial environments in Portugal. *Antimicrob Agents Chemother.* 2007;**51**(6):1946-55. doi: [10.1128/AAC.01412-06](https://doi.org/10.1128/AAC.01412-06). [PubMed: [17371815](https://pubmed.ncbi.nlm.nih.gov/17371815/)].
- Cao V, Lambert T, Nhu DQ, Loan HK, Hoang NK, Arlet G, et al. Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. *Antimicrob Agents Chemother.* 2002;**46**(12):3739-43. doi: [10.1128/AAC.46.12.3739-3743.2002](https://doi.org/10.1128/AAC.46.12.3739-3743.2002). [PubMed: [12435670](https://pubmed.ncbi.nlm.nih.gov/12435670/)].
- Bae IK, Jang SJ, Kim J, Jeong SH, Cho B, Lee K. Interspecies dissemination of the bla gene encoding PER-1 extended-spectrum beta-lactamase. *Antimicrob Agents Chemother.* 2011;**55**(3):1305-7. doi: [10.1128/AAC.00994-10](https://doi.org/10.1128/AAC.00994-10). [PubMed: [21149630](https://pubmed.ncbi.nlm.nih.gov/21149630/)].
- Khoramrooz SS, Sharifi A, Yazdanpanah M, Malek Hosseini SA, Emaneini M, Gharibpour F, et al. High Frequency of Class 1 Integrons in *Escherichia coli* Isolated From Patients With Urinary Tract Infections in Yasuj, Iran. *Iran Red Crescent Med J.* 2016;**18**(1):ee26399. doi: [10.5812/ircmj.26399](https://doi.org/10.5812/ircmj.26399). [PubMed: [26889395](https://pubmed.ncbi.nlm.nih.gov/26889395/)].
- Cocchi S, Grasselli E, Gutacker M, Benagli C, Convert M, Piffaretti JC. Distribution and characterization of integrons in *Escherichia coli* strains of animal and human origin. *FEMS Immunol Med Microbiol.* 2007;**50**(1):126-32. doi: [10.1111/j.1574-695X.2007.00242.x](https://doi.org/10.1111/j.1574-695X.2007.00242.x). [PubMed: [17456180](https://pubmed.ncbi.nlm.nih.gov/17456180/)].
- Sepp E, Stsepetova J, Loivukene K, Trusalu K, Koljalg S, Naaber P, et al. The occurrence of antimicrobial resistance and class 1 integrons among commensal *Escherichia coli* isolates from infants and elderly persons. *Ann Clin Microbiol Antimicrob.* 2009;**8**:34. doi: [10.1186/1476-0711-8-34](https://doi.org/10.1186/1476-0711-8-34). [PubMed: [19995422](https://pubmed.ncbi.nlm.nih.gov/19995422/)].
- Winn WC, Koneman EW. Koneman's color atlas and textbook of diagnostic microbiology. Lippincott Williams & Wilkins; 2006.
- Clinical and Laboratory Standards Institute. *Performance Standards for antimicrobial susceptibility testing; Twenty-Fourth Informational Supplement.* January 2014.
- Lin SP, Liu MF, Lin CF, Shi ZY. Phenotypic detection and polymerase chain reaction screening of extended-spectrum beta-lactamases produced by *Pseudomonas aeruginosa* isolates. *J Microbiol Immunol Infect.* 2012;**45**(3):200-7. doi: [10.1016/j.jmii.2011.11.015](https://doi.org/10.1016/j.jmii.2011.11.015). [PubMed: [22209695](https://pubmed.ncbi.nlm.nih.gov/22209695/)].
- Mohamudha Parveen R, Manivannan S, Harish BN, Parija SC. Study of CTX-M Type of Extended Spectrum beta-Lactamase among Nosocomial Isolates of *Escherichia coli* and *Klebsiella pneumoniae* in South India. *Indian J Microbiol.* 2012;**52**(1):35-40. doi: [10.1007/s12088-011-0140-3](https://doi.org/10.1007/s12088-011-0140-3). [PubMed: [23449681](https://pubmed.ncbi.nlm.nih.gov/23449681/)].
- Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing *Pseudomonas aeruginosa* strains isolated from burn patients. *Burns.* 2010;**36**(1):70-4. doi: [10.1016/j.burns.2009.01.015](https://doi.org/10.1016/j.burns.2009.01.015). [PubMed: [19524369](https://pubmed.ncbi.nlm.nih.gov/19524369/)].
- Dillon B, Thomas L, Mohmand G, Zelynski A, Iredell J. Multiplex PCR for screening of integrons in bacterial lysates. *J Microbiol Methods.* 2005;**62**(2):221-32. doi: [10.1016/j.mimet.2005.02.007](https://doi.org/10.1016/j.mimet.2005.02.007). [PubMed: [16009279](https://pubmed.ncbi.nlm.nih.gov/16009279/)].

18. Goncalves LF, de Oliveira Martins-Junior P, de Melo AB, da Silva RC, de Paulo Martins V, Pitondo-Silva A, et al. Multidrug resistance dissemination by extended-spectrum beta-lactamase-producing *Escherichia coli* causing community-acquired urinary tract infection in the Central-Western Region, Brazil. *J Glob Antimicrob Resist*. 2016;**6**:1-4. doi: [10.1016/j.jgar.2016.02.003](https://doi.org/10.1016/j.jgar.2016.02.003). [PubMed: [27530830](https://pubmed.ncbi.nlm.nih.gov/27530830/)].
19. Ho PL, Poon WW, Loke SL, Leung MS, Chow KH, Wong RC, et al. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary *Escherichia coli* from women. *J Antimicrob Chemother*. 2007;**60**(1):140-4. doi: [10.1093/jac/dkm144](https://doi.org/10.1093/jac/dkm144). [PubMed: [17496058](https://pubmed.ncbi.nlm.nih.gov/17496058/)].
20. Lavigne JP, Marchandin H, Delmas J, Moreau J, Bouziges N, Lecaillon E, et al. CTX-M beta-lactamase-producing *Escherichia coli* in French hospitals: prevalence, molecular epidemiology, and risk factors. *J Clin Microbiol*. 2007;**45**(2):620-6. doi: [10.1128/JCM.01917-06](https://doi.org/10.1128/JCM.01917-06). [PubMed: [17108071](https://pubmed.ncbi.nlm.nih.gov/17108071/)].
21. Shanthi M, Sekar U. Extended spectrum beta lactamase producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *J Assoc Physicians India*. 2010;**58 Suppl**:41-4. [PubMed: [21568008](https://pubmed.ncbi.nlm.nih.gov/21568008/)].
22. Pourakbari B, Ferdosian F, Mahmoudi S, Teymuri M, Sabouni F, Heydari H, et al. Increase resistant rates and ESBL production between *E. coli* isolates causing urinary tract infection in young patients from Iran. *Braz J Microbiol*. 2012;**43**(2):766-9. doi: [10.1590/S1517-83822012000200041](https://doi.org/10.1590/S1517-83822012000200041). [PubMed: [24031888](https://pubmed.ncbi.nlm.nih.gov/24031888/)].
23. Latifpour M, Gholipour A, Damavandi MS. Prevalence of Extended-Spectrum Beta-Lactamase-Producing *Klebsiella pneumoniae* Isolates in Nosocomial and Community-Acquired Urinary Tract Infections. *Jundishapur J Microbiol*. 2016;**9**(3):ee31179. doi: [10.5812/jjm.31179](https://doi.org/10.5812/jjm.31179). [PubMed: [27226874](https://pubmed.ncbi.nlm.nih.gov/27226874/)].
24. Afzali H, Firoozeh F, Amiri A, Moniri R, Zibaei M. Characterization of CTX-M-Type Extend-Spectrum beta-Lactamase Producing *Klebsiella* spp. in Kashan, Iran. *Jundishapur J Microbiol*. 2015;**8**(10):ee27967. doi: [10.5812/jjm.27967](https://doi.org/10.5812/jjm.27967). [PubMed: [26587221](https://pubmed.ncbi.nlm.nih.gov/26587221/)].
25. Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Aldisio E, Marchese AE, et al. Antibiotic trends of *Klebsiella pneumoniae* and *Acinetobacter baumannii* resistance indicators in an intensive care unit of Southern Italy, 2008-2013. *Antimicrob Resist Infect Control*. 2015;**4**:43. doi: [10.1186/s13756-015-0087-y](https://doi.org/10.1186/s13756-015-0087-y). [PubMed: [26539294](https://pubmed.ncbi.nlm.nih.gov/26539294/)].
26. Feizabadi MM, Delfani S, Raji N, Majnooni A, Aligholi M, Shahcheraghi F, et al. Distribution of bla(TEM), bla(SHV), bla(CTX-M) genes among clinical isolates of *Klebsiella pneumoniae* at Labbafinejad Hospital, Tehran, Iran. *Microb Drug Resist*. 2010;**16**(1):49-53. doi: [10.1089/mdr.2009.0096](https://doi.org/10.1089/mdr.2009.0096). [PubMed: [19961397](https://pubmed.ncbi.nlm.nih.gov/19961397/)].
27. Barguigua A, El Otmani F, Talmi M, Bourjilat F, Haouzane F, Zerouali K, et al. Characterization of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates from the community in Morocco. *J Med Microbiol*. 2011;**60**(Pt 9):1344-52. doi: [10.1099/jmm.0.032482-0](https://doi.org/10.1099/jmm.0.032482-0). [PubMed: [21546559](https://pubmed.ncbi.nlm.nih.gov/21546559/)].
28. Baudry PJ, Nichol K, DeCorby M, Lagace-Wiens P, Olivier E, Boyd D, et al. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing *Escherichia coli* from Canadian intensive care units: the 1st report of QepA in North America. *Diagn Microbiol Infect Dis*. 2009;**63**(3):319-26. doi: [10.1016/j.diagmicrobio.2008.12.001](https://doi.org/10.1016/j.diagmicrobio.2008.12.001). [PubMed: [19216943](https://pubmed.ncbi.nlm.nih.gov/19216943/)].
29. Ruppe E, Hem S, Lath S, Gautier V, Arieu F, Sarthou JL, et al. CTX-M beta-lactamases in *Escherichia coli* from community-acquired urinary tract infections, Cambodia. *Emerg Infect Dis*. 2009;**15**(5):741-8. doi: [10.3201/eid1505.071299](https://doi.org/10.3201/eid1505.071299). [PubMed: [19402960](https://pubmed.ncbi.nlm.nih.gov/19402960/)].
30. Kiiru J, Butaye P, Goddeeris BM, Kariuki S. Analysis for prevalence and physical linkages amongst integrons, ISEcp1, ISCR1, Tn21 and Tn7 encountered in *Escherichia coli* strains from hospitalized and non-hospitalized patients in Kenya during a 19-year period (1992-2011). *BMC Microbiol*. 2013;**13**:109. doi: [10.1186/1471-2180-13-109](https://doi.org/10.1186/1471-2180-13-109). [PubMed: [23682924](https://pubmed.ncbi.nlm.nih.gov/23682924/)].